Inteum Company
Links
Visible Legacy
RSS
News & Resources
Inteum Company News
Inteum Library
Subscribe
Search Results - lawrence+tumey
3
Results
Sort By:
Published Date
Updated Date
Title
ID
Descending
Ascending
Targeted Legumain-Cleavable Top1i ADC Platform
Tech Briefs: RSS Drafter said: This technology introduces a legumain-cleavable antibody drug complex (ADC) that delivers topoisomerase inhibitors directly into tumor cells using a short, polar linker design. The platform employs low-potency Top1i derivatives that maintain strong in vivo efficacy while potentially improving safety, offering a balanced...
Published: 12/10/2025
|
Inventor(s):
Lawrence Tumey
,
Nicholas Bianchi
,
Victor Ojo
Keywords(s):
Technologies
Category(s):
Campus > Binghamton University
Hydrophilic Asn-Asn-Linker Adcs for Potent and Stable Targeted Immunotherapy
This invention introduces hydrophilic TLR7 agonist antibody drug conjugates using a short Asn Asn linker that improves solubility, stability, and pharmacokinetics. By enabling precise site specific conjugation with reduced aggregation and strong innate immune activation, the platform delivers potent antitumor responses across multiple solid tumor indications. Background:...
Published: 12/9/2025
|
Inventor(s):
Lawrence Tumey
,
Mohan Mullapudi
Keywords(s):
Technologies
Category(s):
Campus > Binghamton University
Dual Payload Antibody Conjugates for Combined Cytotoxic and Immune Stimulatory Cancer Therapy
This invention introduces a dual payload antibody drug conjugate platform that delivers both a potent cytotoxic agent and a TLR7 agonist to tumors with controlled, site specific attachment. By uniting targeted cell killing with localized immune activation in a single biologic, the approach improves therapeutic index, overcomes resistance, and enhances...
Published: 12/9/2025
|
Inventor(s):
Lawrence Tumey
,
Victor Ojo
Keywords(s):
Technologies
Category(s):
Campus > Binghamton University